Home » Authors » Kim Coghill

Articles by Kim Coghill

Focused On Brain, CNS Disorders, Saegis Raises $30M In Its Series B

Nov. 19, 2003

Phoenix Pharmacologics Starts Phase III Study In Liver Cancer

Nov. 19, 2003

Allos Presents RSR13 Data; NDA Completion Expected This Year

Nov. 18, 2003

Allos Presents RSR13 Data; NDA Completion Expected This Year

Nov. 18, 2003

U.S. Federal Survey Probes Biotech Growth, Hindrances

Nov. 17, 2003

Dendreon Regains Asian Provenge Rights From Kirin, Avoids IP Issues

Nov. 17, 2003

Dendreon Regains Asian Provenge Rights From Kirin, Avoids IP Issues

Nov. 17, 2003

U.S. Federal Survey Probes Biotech Growth, Hindrances

Nov. 17, 2003

Preparing For Estrasorb Launch, Novavax Publicly Raises $27.7M

Nov. 14, 2003

Preparing For Estrasorb Launch, Novavax Publicly Raises $27.7M

Nov. 14, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...